Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU4-44P is a predicted non-functional copy (pseudogene) related to the U4 small nuclear RNA (snRNA) genes, specifically member 44 of this family[6]. While functional U4 snRNAs, such as RNU4-2, are components of the spliceosome complex responsible for pre-mRNA splicing, and play crucial roles in processes like neurodevelopment and can cause disease if disrupted[1][2][3][5], pseudogenes like RNU4-44P derive from duplication or retrotransposition events. They typically lack regulatory or coding elements needed for proper expression or function, and thus, do not produce a functional RNA molecule or protein[6]. As a pseudogene, RNU4-44P does not contribute functional RNA and is not considered a direct biological, therapeutic, or disease-relevant target[6]. No evidence exists that RNU4-44P plays a direct biological role, acts as a therapeutic target, or is implicated in disease. Furthermore, no drugs, safety concerns, biomarkers, or disease indications are associated with RNU4-44P under current knowledge[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 44, pseudogene (RNU4-44P).